THE discovery of the antiviral properties of 5-iodo-2'-deoxyuridine (IDU), arabinoside cytosine (ARAC), L-asparaginase and of some derivatives of rifampicin holds out new perspectives for the treatment of severe viral diseases, such as herpetic encephalitis and opportunistic viral illnesses in the immuno-depressed host. For these infections a valuable chemotherapeutic regimen still remains to be discovered. Therefore, we have invesigated in vitro the antiviral activity of IDU, Ara-C and Lasparaginase and the efficacy of their combinations against a strain of herpes simplex virus. To keep this note brief, we will report here only a few preliminary results obtained in our laboratory with the combinations Ara-C/L-asparaginase and IDU/L-asparaginase.
The antiviral activity of these two associations of antiviral drugs was tested using two methods: firstly, the technique using the inhibition of the formation of viral plaques; and secondly a micromethod based on a technique used by others to investigate mechanisms of cellular immunity (Takasugi & Klein, 1970) . Each well of a Terasaki's plaque, containing 500 cells, was inoculated with 10 ,ul of medium 199 with 1000 TCD50 of the test virus. After 2 hr, the wells were emptied and 10 ju.l of medium 199 containing the combinations of drugs to be tested were added to the infected cells. The result was evaluated after 48 hr as a 100%°inhibition of the cytopathogenic effects (CPE) when no such effects could be found. For each concentration of the drugs used here, whether alone or in combination, 250 wells were examined. The results obtained by the two methods were concordant. As shown in Fig. 1 , the combination Ara-C/L-asparaginase was found to be synergistic on the test strain. On the other hand, the combination IDU/L-asparaginase was only additive.
The synergistic effect of Ara-C and L-asparaginase when used in combination against herpes simplex virus was tested here on different cells (rabbit kidney, chicken fibroblasts and HEP2). It should be pointed out, however, that the concentration of Lasparaginase required to produce 100% inhibition of CPE varied to a certain extent depending on the type of cell used. This might be explained by variable content in L-asparaginase of the cells used in these experiments.
The synergistic effect found in these studies might prove to be of clinical interest since it might allow a reduction in the toxicity caused by both Ara-C (on bone marrow) and L-asparaginase (on the liver) and still obtain a significant antiviral effect.
Therefore, these studies suggest that a clinical controlled trial might be undertaken in patients presenting serious herpetic diseases such as encephalitis. The respective efficacy of Ara-C alone, which is already used (Juel-Jensen, 1970) , and of the combination Ara-C/L-asparaginase should be evaluated. Therapy with L-asparaginase alone cannot be safely recommended, however, since in vitro very high levels of that drug, that-cannot be obtained in body fluids, were not capable of 100% inhibition of CPE.
